FIELD: medicine.
SUBSTANCE: described is antibody or one of its functional fragments, which have high affinity to receptor of human insulin-like growth factor (IGF-IR) and inhibiting binding of IGFI with IGF-IR and binding of IGF2 with IGF-IR. Claimed is hybridoma, producing described antibody. Invention also includes application of antibody as therapeutic means for preventive and/or therapeutic treatment of cancer, during which takes place overexpression of IGF-IR, stimulated either by IGF-1, and/or by IGF-2, or any other pathology, connected with overexpression of said receptor, as well as in methods or in sets for diagnostics of diseases, associated with overexpression of receptor IGF-IR and/or hybrid receptor IGF-1/Insulin.
EFFECT: invention makes it possible to obtain antibody, which specifically with high affinity recognises IGF-IR and which also inhibits not only binding of IGF1 with IGF-IR, but also binding of IGF2 with IGF-IR.
51 cl, 11 dwg, 4 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL ANTI-IGF-IR AND THEIR APPLICATION | 2005 |
|
RU2406729C2 |
| RECEPTOR ANTAGONISTS FOR TREATING METASTATIC CANCER | 2009 |
|
RU2455026C2 |
| PDGFRα ANTIBODIES FOR TREATING SECONDARY BONE TUMOUR | 2006 |
|
RU2502523C2 |
| RECEPTOR IGF-I ANTIBODIES | 2003 |
|
RU2421465C2 |
| COMPOSITION OF HER2 ANTIBODIES | 2005 |
|
RU2361880C2 |
| EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY | 2013 |
|
RU2652880C2 |
| BINDING PROTEINS SPECIFIC TO INSULIN-LIKE GROWTH FACTORS, AND USING THEM | 2013 |
|
RU2549703C2 |
| BISPECIFIC ANTIBODIES | 2011 |
|
RU2573588C2 |
| ANTI-IGF-1R ANTIBODY AND USE THEREOF AS AN ADDRESS VECTOR FOR CANCER TREATMENT | 2015 |
|
RU2698977C2 |
| METHOD FOR IDENTIFICATION AND/OR VERIFICATION OF INHIBITORS OF RECEPTOR TYROSINE KINASES | 2003 |
|
RU2366716C2 |
